Apellis Pharmaceuticals Inc BPA
Quel est le BPA de Apellis Pharmaceuticals Inc?
Le BPA de Apellis Pharmaceuticals Inc est N/A
Quelle est la définition de BPA?
Le bénéfice par action (BPA) est la partie du bénéfice d’une société affectée à chaque action en circulation d’actions ordinaires. Il est ajusté pour tenir compte de la dilution et calculé sur douze mois.
Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. Preferred stock rights have precedence over common stock. Therefore, dividends on preferred shares are subtracted before calculating the EPS. When preferred shares are cumulative, annual dividends are deducted whether or not they have been declared. Dividends in arrears are not relevant when calculating EPS. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.
Que fait Apellis Pharmaceuticals Inc?
apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.